Across the collection
Which organs, which outcomes?
Damaged kidneys, the digestive tract, liver fat and muscle under strain give these compounds different places in the research.
Kidney disease
Semaglutide’s FLOW trial treated people with type 2 diabetes and chronic kidney disease, recording fewer major kidney events in a combined outcome that also included kidney or cardiovascular death. The MOTS-c dialysis cohort measured a circulating biomarker, associating higher readings with a worse combined outcome.
I’d put these studies near each other because they reveal different things about bodies already under strain. One compares treatment; the other observes a blood measurement. Their proximity invites a question about kidney disease while preserving that distinction.
Heart events; pulse changes
SELECT counted cardiovascular death, nonfatal heart attack and nonfatal stroke in adults with established cardiovascular disease and overweight or obesity without diabetes. It found a reduction with semaglutide. In the retatrutide Phase 2 obesity trial, heart rate increased in a dose-related pattern. Its later cardiovascular significance remains unknown.
The event findings and pulse observations answer different questions. I’d leave the pulse observation unresolved until longer outcome trials explain its significance.
Weight and tissues
The direct tirzepatide–semaglutide comparison provides the firmest weight comparison between those medicines in these sources. Retatrutide’s liver-fat substudy measured fat within the liver in a smaller, different population. MOTS-c’s muscle performance findings came from mice.
I’d resist arranging these results into a single podium. The specific jobs matter more: changing body weight, reducing liver fat, performing a mouse muscle test. A result retains its value when its scope stays visible.
Tolerability
The semaglutide safety review and tirzepatide trial analysis give digestive and biliary concerns a substantial place in the account. Retatrutide still needs longer-term safety and outcome evidence. MOTS-c still needs human trials of administration that establish benefit and characterize harm.
The individual pages carry the populations, figures and regulatory limits. An organ’s whole burden interests me: the disease it starts with, the improvement measured and the difficulties treatment can add.